Stay updated on FT538 with Daratumumab in AML Clinical Trial
Sign up to get notified when there's something new on the FT538 with Daratumumab in AML Clinical Trial page.

Latest updates to the FT538 with Daratumumab in AML Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference12%

- Check25 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.3%

- Check40 days agoChange DetectedUpdated revision to v3.0.2 and removed the Back to Top link; no changes to core content, pricing, stock, or time slots.SummaryDifference0.7%

- Check47 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.7%

- Check54 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while several location-related terms have been removed.SummaryDifference16%

- Check68 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%

Stay in the know with updates to FT538 with Daratumumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FT538 with Daratumumab in AML Clinical Trial page.